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drugs, such as age, bronchodilator reversibility, and history of or
current tobacco use. Naturally, some criteria may be warranted
by the trial methodology to reach the primary endpoint. For example,
the minimum exacerbation rate in the previous year may guarantee
a sufﬁcient number of events to avoid studies being prolonged if
the primary endpoint is the time until the ﬁrst exacerbation. These
administrative and ﬁnancial constraints should not, however,
affect the scientiﬁc value of these studies, and the results should remain
able to be extrapolated to excluded populations.
Patients included in RCTs are young, are recently diagnosed,
are healthy other than their asthma, have moderate to severe rather
than very severe asthma, and have never been heavy smokers.
Because current guidelines such as GINA rely on results from such
exclusive RCTs, this calls into question the extent to which these
guidelines are applicable to daily practice. n
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A Potential Link between Serum Low-Density
Lipoproteins and Asthma
To the Editor:
We read with great interest the article by Barochia and colleagues
about the relationship between serum lipid and apolipoprotein
levels and asthma (1). As highlighted by the authors, although
apolipoproteins and lipoproteins are important modulators of
inﬂammation, varying relationships exist between these parameters
and asthma (2), and the data are still not conclusive. Indeed, it is
still not fully clear which lipoproteins are more strictly associated
with asthma development and progression (severity).
Barochia and colleagues report a positive correlation between
FEV1% predicted and high-density lipoprotein (HDL)-cholesterol
or apolipoprotein A-I in atopic asthma, and they also suggest that
this correlation may be largely mediated by the subfraction of
large HDL particles. This ﬁnding seems to complement what we
Table 1. Ranking of the Most Discriminating Criteria Used in
Randomized Controlled Severe Asthma Trials
Criterion
Patients Excluded Because of
the Criterion (%)
Reversibility 73
Exacerbation rate 58
Absence of oral
corticosteroid treatment
50
No ICU admission history 31
Maximum FEV1 24
Minimum FEV1 23
Smoking status 23
Age 10
BMI/weight 3
Comorbidities 2
Definition of abbreviations: BMI = body mass index; ICU = intensive care
unit.
Percentages are out of the total number of patients in the COBRA (Cohorte
Obstruction Bronchique et Asthme) cohort.
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reported in 2013 in another study on the association between
asthma and low-density lipoprotein (LDL) subclasses (3): We
found a positive correlation between FEV1% predicted and larger
LDL particles (LDL-1), as well as negative correlation between
FEV1% predicted and smaller, more dense LDL particles (LDL-3).
In that study, we hypothesized that LDL could represent a potent
trigger for the inﬂammatory changes of the airways. It was
somewhat surprising that the Barochia and colleagues did not
mention our study, as it still represents the only study that has
assessed the full spectrum of all seven LDL subclasses in asthma.
As highlighted by the European Panel on LDL Subclasses
(4), the methodology used for assessing lipoprotein subclasses is
crucial. In the present study, Barochia and colleagues used nuclear
magnetic resonance spectroscopy to assess the lipoprotein particles;
yet with this methodology, they were able to assess only a few
subclasses with low resolution (e.g., three very-low-density
lipoprotein subclasses [large, medium, and small very-low-density
lipoprotein], two LDL subclasses [large and small LDL], and three
HDL subclasses [large, medium, and small HDL]). Methodologies
are available to assess lipoprotein subfractions with a higher degree
of resolution, and in our study, we used a methodology of gel
electrophoresis (Lipoprint; Quantimetrix Corporation, Redondo
Beach, CA) that is able to distinguish seven LDL subclasses (3) as
well as 10 HDL subclasses (5).
Of interest, in our study (3), we reported that asthma was
associated with smaller LDL particles, which are proinﬂammatory
particles (6), and in the present study, Barochia and colleagues
reported that asthma was associated with larger HDL particles,
which seem to be dysfunctional HDLs with proinﬂammatory
properties (7). We therefore believe that the ﬁndings of the two
studies support the concept that small LDLs could lead to the
ampliﬁcation of the inﬂammatory cascade in asthma, and we
advocate for larger studies speciﬁcally designed to conﬁrm the
association between asthma and dyslipidemia and to elucidate the
underlying mechanisms. n
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Reply
From the Authors:
We thank Drs. Scichilone and Rizzo for bringing to our attention
their study investigating the association between lung function in
patients with asthma and subclasses of low-density lipoproteins
(LDLs), as measured by gel electrophoresis (1). In particular, the
ﬁnding that the LDL-3 subclass is negatively correlated with FEV1
after adjusting for differences in age, sex, and body mass index is
intriguing. We believe their result is consistent with the negative
association we found between percentage predicted FEV1 and
subgroups of LDL particles, as measured by nuclear magnetic
resonance (NMR) spectroscopy in atopic patients with asthma.
We respectfully point out that we did not report an association
between asthma and large high-density lipoprotein (HDL) particles
but, rather, a positive association between FEV1% predicted and
the concentration of large HDLNMR particles in patients with
asthma (2). Thus, we postulate that large HDLNMR particles may
modulate the severity of airﬂow obstruction in atopic patients
with asthma.
The study of the signiﬁcance of lipoproteins in asthma is in its
early stages yet. We agree with Drs. Scichilone and Rizzo that
additional studies investigating the composition and function of
subclasses of lipoprotein molecules, and the various methods used to
measure them, will be necessary to better characterize the precise
roles they may be playing in the pathogenesis of asthma. n
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